The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-7364

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma ; volume:10 ; number:1 ; day:28 ; month:12 ; year:2016 ; pages:1-2 ; date:12.2016
Human genomics ; 10, Heft 1 (28.12.2016), 1-2, 12.2016

Keyword: Krebs
Onkologie

Creator: Chang, Kuang-Leei

Contributor: Lee, Ming-Yung
Chao, Wan-Ru
Han, Chih-Ping
SpringerLink (Online service)

DOI: 10.1186/s40246-016-0096-9

URN: urn:nbn:de:1111-201701267799

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Chang, Kuang-Leei
Lee, Ming-Yung
Chao, Wan-Ru
Han, Chih-Ping
SpringerLink (Online service)

Other Objects (12)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component

KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Is HER2 amplification predictable by digital immunohistochemistry?

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas

KRAS mutations in squamous cell carcinomas of the lung

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS G12D or KRAS G12V mutations

Related objects

Reset password